Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today that the Company will present Phase I results from their ACTolog® program IMA101 at the 35th Annual SITC Meeting, held virtually from November 9-14, 2020.
by eazee-designstudio
The funding round led by Ancora Finance Group and Wellington Partners will bolster Koa Health’s growth ambitions to make mental health treatment more accessible with its wide range of digital solutions.
